PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsFormoterol
Foradil, Duoresp spiromax(formoterol)
Aerosphere, Breyna, Budesonide/Formoterol Teva Pharma B.V, CHF 5993 Chiesi Farmaceutici S.p.A, Duaklir, Duaklir Genuair, Dulera, Formoterol, Genuair, Perforomist, Riarify, Spiromax, Symbicort, Symbicort Aerosphere, Trimbow, Trydonis (formoterol) is a small molecule pharmaceutical. Formoterol was first approved as Foradil on 2001-02-16. It is used to treat asthma and bronchial spasm in the USA. It has been approved in Europe to treat asthma and chronic obstructive pulmonary disease. The pharmaceutical is active against beta-2 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Perforomist (generic drugs available since 2021-06-22, discontinued: Foradil, Foradil certihaler)
Combinations
Bevespi aerosphere, Breztri aerosphere, Duaklir, Dulera, Symbicort, Symbicort aerosphere (generic drugs available since 2021-06-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aclidinium bromide
+
Formoterol fumarate
Tradename
Company
Number
Date
Products
DUAKLIR PRESSAIRCovis PharmaN-210595 RX2019-03-29
1 products, RLD, RS
Budesonide
+
Formoterol fumarate
Tradename
Company
Number
Date
Products
SYMBICORT AEROSPHEREAstraZenecaN-216579 RX2023-04-28
1 products, RLD, RS
Budesonide
+
Formoterol fumarate
+
Glycopyrrolate
Tradename
Company
Number
Date
Products
BREZTRI AEROSPHEREAstraZenecaN-212122 RX2020-07-23
1 products, RLD, RS
Budesonide
+
Formoterol fumarate dihydrate
Tradename
Company
Number
Date
Products
SYMBICORTAstraZenecaN-021929 RX2006-07-21
2 products, RLD, RS
Formoterol fumarate
Tradename
Company
Number
Date
Products
PERFOROMISTMylanN-022007 RX2007-05-11
1 products, RLD, RS
Show 2 discontinued
Formoterol fumarate
+
Glycopyrrolate
Tradename
Company
Number
Date
Products
BEVESPI AEROSPHEREAstraZenecaN-208294 RX2016-04-25
1 products, RLD, RS
Formoterol fumarate
+
Mometasone furoate
Tradename
Company
Number
Date
Products
DULERAOrganonN-022518 RX2010-06-22
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
bevespi aerosphereNew Drug Application2023-03-24
bretzriNew Drug Application2020-07-23
breynaANDA2020-09-24
breztriNew Drug Application2022-01-26
budesonide and formoterol fumarate dihydrateNDA authorized generic2023-03-02
duaklir pressairNew Drug Application2022-08-01
duleraNew Drug Application2023-03-24
foradilNew Drug Application2012-03-01
formoterol fumarateANDA2024-01-11
perforomistNew Drug Application2019-05-01
Show 1 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
asthmaEFO_0000270D001249J45
bronchial spasm—D001986—
Agency Specific
FDA
EMA
Expiration
Code
BUDESONIDE / FORMOTEROL FUMARATE / GLYCOPYRROLATE, BREZTRI AEROSPHERE, ASTRAZENECA AB
2023-07-23NC
FORMOTEROL FUMARATE / MOMETASONE FUROATE, DULERA, ORGANON LLC
2023-02-12PED
Patent Expiration
Patent
Expires
Flag
FDA Information
Budesonide / Formoterol Fumarate / Glycopyrrolate, Breztri Aerosphere, Astrazeneca Ab
113314422038-05-10DP
88152582031-03-17U-2889
83242662030-05-28U-2889
87038062030-05-28U-2889
88087132030-05-28DPU-2889
94631612030-05-28DPU-2889
Budesonide / Formoterol Fumarate, Symbicort Aerosphere, Astrazeneca
94150092030-05-28U-2889, U-3203
107167532030-05-28DPU-2889, U-3203
Budesonide / Formoterol Fumarate Dihydrate, Symbicort, Astrazeneca
86161962029-04-07DP
85285452028-10-16DP
83876152027-03-26DP
75879882026-04-10DP
88756992024-11-10DP
77593282023-01-29DPU-2001, U-2002, U-2122
81432392023-01-29DPU-2001, U-2002, U-2122
85751372023-01-29DPU-2001, U-2002, U-2122
101662472023-01-29DPU-2001, U-2002, U-2122
113115582023-01-29DP
Aclidinium Bromide / Formoterol Fumarate, Duaklir Pressair, Covis
100859742029-03-13DPU-2513
110005172029-03-13DPU-2513
80518512027-04-22DP
RE464172025-02-10DS, DPU-2513
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AC: Selective beta-2-adrenoreceptor agonist inhalants
— R03AC13: Formoterol
— R03AK: Adrenergics inhalants in combination with corticosteroids or other drugs, excl. anticholinergics
— R03AK07: Formoterol and budesonide
— R03AK08: Formoterol and beclometasone
— R03AK09: Formoterol and mometasone
— R03AK11: Formoterol and fluticasone
— R03AL: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
— R03AL05: Formoterol and aclidinium bromide
— R03AL07: Formoterol and glycopyrronium bromide
— R03AL09: Formoterol, glycopyrronium bromide and beclometasone
— R03AL10: Formoterol and tiotropium bromide
— R03AL11: Formoterol, glycopyrronium bromide and budesonide
— R03C: Adrenergics for systemic use
— R03CC: Selective beta-2-adrenoreceptor agonists, systemic
— R03CC15: Formoterol
HCPCS
Code
Description
J7605
Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms
J7606
Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms
J7640
Formoterol, inhalation solution, compounded product, administered through dme, unit dose form, 12 micrograms
Clinical
Clinical Trials
572 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AsthmaD001249EFO_0000270J4523461094453268
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.92146855932236
EmphysemaD004646EFO_0000464J43——44—8
Disease progressionD018450————1337
Chronic bronchitisD029481—J42——23—5
BronchiectasisD001987HP_0002110J47——1214
Exercise-induced asthmaD001250—J45.990—111—3
Obstructive lung diseasesD008173HP_0006536——221—3
Respiratory tract infectionsD012141—J06.9—1—1—2
InflammationD007249MP_0001845——1—1—2
Show 12 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic bronchopulmonary aspergillosisD001229EFO_0007140B44.81—44——4
Covid-19D000086382—U07.1—22——3
Respiratory insufficiencyD012131HP_0002093J96.9——1——1
PneumoniaD011014EFO_0003106———1——1
HypoxiaD000860HP_0012418R09.02——1——1
HypersensitivityD006967HP_0012393T78.40—11——1
SmokingD012907EFO_0004318———1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Medication adherenceD055118EFO_0006344—22——13
Bronchiolitis obliteransD001989EFO_0007183——2———2
Interstitial lung diseasesD017563HP_0006530J84.89—1———1
Cryptogenic organizing pneumoniaD018549EFO_1001300J84.116—1———1
Respiratory distress syndromeD012128EFO_1000637J80—1———1
Idiopathic pulmonary fibrosisD054990—J84.112—1———1
Alzheimer diseaseD000544EFO_0000249F03—1———1
Cognitive dysfunctionD060825HP_0001268G31.84—1———1
Airway obstructionD000402———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———6———28
Lung neoplasmsD008175HP_0100526C34.901————1
Precancerous conditionsD011230——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CoughD003371HP_0012735R05————22
Personal satisfactionD010549——————11
Patient satisfactionD017060——————11
Type 1 diabetes mellitusD003922EFO_0001359E10————11
Allergic rhinitisD065631—J30.9————11
Bronchial hyperreactivityD016535——————11
HypertrophyD006984EFO_0002460—————11
Non-small-cell lung carcinomaD002289——————11
Drug-related side effects and adverse reactionsD064420—T88.7————11
ObesityD009765EFO_0001073E66.9————11
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFormoterol
INNformoterol
Description
N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide is a phenylethanoloamine having 4-hydroxy and 3-formamido substituents on the phenyl ring and an N-(4-methoxyphenyl)propan-2-yl substituent. It is a member of phenols, a member of formamides, a secondary amino compound, a secondary alcohol and a member of phenylethanolamines.
Classification
Small molecule
Drug classbronchodilators (phenethylamine derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1
Identifiers
PDB—
CAS-ID73573-87-2
RxCUI—
ChEMBL IDCHEMBL1256786
ChEBI ID63082
PubChem CID3410
DrugBankDB00983
UNII ID5ZZ84GCW8B (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Duaklir – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Dulera – Organon
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Dulera – Merck Sharp & Dohme
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Breztri aerosphere – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Bevespi aerosphere – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Symbicort – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Formoterol
+
Budesonide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Formoterol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Formoterol
+
Mometasone
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,876 documents
View more details
Safety
Black-box Warning
Black-box warning for: Foradil
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
53,813 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use